Management and Clinical Aspects of Burned Patients Affected by SARS-COV2

Abstract

At the end of January 2020, SARS-CoV-2 started escalating worldwide. COVID-19 can exert its effects on immunity, inflammation, and multi-organ system disease, common denominators with the burn injury. The pandemic required major efforts to Burn centres in order to preserve burn patients’ care and contribute to the health care response. In our Burn Unit we autonomously developed a protocol for patients acceptance and surveillance of the hospitalized ones and the personnel. We briefly describe our experience with six cases of burn patients infected by SARS-CoV-2 highlighting the overlap between medical treatment of burn patients and COVID-19 patients. To avoid viral spreading epidemiologic control is essential, especially preventive measures such as isolation of infected patients and identification of the source of infection. In our surgical practice, we increased the use of enzymatic debridement avoiding procedures with a high risk of viral particles spreading. Personnel protection and dedicated pathways have been planned, optimizing air circulation and disinfection. Vaccines represent the best hope for the global population to stop the viral spread, despite new variants outbreaks.

Bromelain‐based enzymatic burn debridement: A systematic review of clinical studies on patient safety, efficacy and long‐term outcomes

“…NXB proved valuable during the COVID‐19 pandemic which pushed the healthcare system to its limit due to staff shortages, and high Intensive Care Unit (ICU) demands (e.g., ventilators, transfusion of blood products, operating room supplies, etc.). In an attempt to save resources, there was a shift towards non‐surgical care of burn patients worldwide 19–21 . For example, several authors reported their successful experiences with the use of NXB during the pandemic.…”

“…For example, several authors reported their successful experiences with the use of NXB during the pandemic. They believed BBD was a suitable alternative to surgery with the highest level of evidence globally 20,22,23 …”

“…In an attempt to save resources, there was a shift towards non-surgical care of burn patients worldwide. [19][20][21] For example, several authors reported their successful experiences with the use of NXB during the pandemic. They believed BBD was a suitable alternative to surgery with the highest level of evidence globally.…”

“…They believed BBD was a suitable alternative to surgery with the highest level of evidence globally. 20,22,23 Decades of translational research on NXB led to its final approval for clinical use in 2012 by the European Medicines Agency (EMA). [24][25][26][27][28][29][30][31][32][33][34][35][36][37] The centralized European Union approval was based on the results of 7 clinical trials.…”